Kristy Shield‐Artin

Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial

Katrin Marie Sjoquist, Alexander Dobrovic, Kristy P. Robledo, Ksenija Nesic et autres

au, gb, fr, sg (code pays fourni par la source)

Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial

Chee Khoon Lee, Apriliana E. R. Kartikasari, Nirashaa Bound, Katherine E. Francis et autres

au (code pays fourni par la source)

Generation of a PARPi-sensitive homozygous BRCA1-methylated OVCAR8 cell line using targeted CRISPR gene editing

Ksenija Nesic, Sally Beard, Lijun Xu, Olga Kondrashova et autres

au (code pays fourni par la source)

747P SOLACE2: A phase II randomized trial of olaparib (O) and durvalumab (D) with or without low dose cyclophosphamide (LDCy) in platinum-sensitive recurrent ovarian cancer (PSROC)

Clare L. Scott, Michael Friedländer, Katherine E. Francis, Apriliana E. R. Kartikasari et autres

au, es (code pays fourni par la source)

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance

Ksenija Nešić, John J. Krais, Yifan Wang, Cassandra J. Vandenberg et autres

au, us, gb, ca (code pays fourni par la source)

CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer

Haineng Xu, Sarah B. Gitto, Gwo‐Yaw Ho, Sergey Medvedev et autres

us, au, ca (code pays fourni par la source)

Targeting homologous recombination deficiency in uterine leiomyosarcoma

Genevieve Dall, Cassandra J. Vandenberg, Ksenija Nesic, Gayanie Ratnayake et autres

au (code pays fourni par la source)

Supp Table 1 from Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Olga Kondrashova, Minh Tho Nguyen, Kristy Shield‐Artin, Anna V. Tinker et autres

Supplementary Tables and Supplementary Figures 1 through 11 from Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Olga Kondrashova, Minh Tho Nguyen, Kristy Shield‐Artin, Anna V. Tinker et autres

Supp Video from Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Olga Kondrashova, Kristy Shield‐Artin, Anna V. Tinker, Nelson N.H. Teng et autres

Supp Table 4 from Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Olga Kondrashova, Minh Nguyen, Kristy Shield‐Artin, Anna V. Tinker et autres

Supp Table 4 from Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Olga Kondrashova, Kristy Shield‐Artin, Anna V. Tinker, Nelson N.H. Teng et autres